In Q2, the FDA approved two biosimilars in the ustekinumab and bevacizumab markets and four biosimilars were launched within ...

Tiffany E Jiang , Reshma Ramachandran , and Joshua J Skydel argue that US requirements for interchangeability are not supported by evidence and hamper use of biosimilars Biological medicines ...

Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.

On July 24, 2025, the Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) convened the second of three public ...

Health plans should directly contract with drug manufacturers to provide medications at transparent and affordable prices, ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Merck's Q2 2025 earnings call reveals revenue of $15.8B, strategic growth plans with a $3B reinvestment initiative, and confidence in driving ...

Accessa is proud to announce the launch of OSTEOACCES, the very first therapeutic adherence program under its new ADHAESIOTM line, designed to promote medication adherence through a patient-centered ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Intas Pharma has announced the appointment of Umesh Gupta as Associate Executive Vice President - Manufacturing Operations.In ...